Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events

Current Opinion in Lipidology

Volumn 21, Issue 1, 2010, Pages 70-75

  Miida, Takashi ^a   Hirayama, Satoshi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelial lipase; HDL; Lipoprotein lipase; Triglyceride

Indexed keywords

ANGIOPOIETIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PROTEIN ANGPTL 3; PROTEIN ANGPTL 4; PROTEIN ANGPTL 5; PROTEIN ANGPTL 6; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CAROTID ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMORAL ARTERY; HUMAN; LIPOPROTEIN METABOLISM; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOPOIETINS; ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; MUTATION; TRIGLYCERIDES;

MUS;

EID: 77649099496     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328333269e     Document Type: Review

References (46)

1. Hasham SN, Pillarisetti S. Vascular lipases, inflammation and atherosclerosis. Clin Chim Acta 2006; 372:179-183.
2. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 2008; 18: 6-1 4.
3. Li C. Genetics and regulation of angiopoietin-like proteins 3 and 4. Curr Opin Lipidol 2006; 17:152-156.
4. Katoh Y, Katoh M. Comparative integromics on angiopoietin family members. Int J Mol Med 2006; 17:1145-1149.
5. Koishi R, AndoY, OnoM, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet 2002; 30:151-157.
6. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002; 277:33742-33748
7. HUGO gene nomenclature committee. http://www.genenames.org/.
8. Romeo S, Yin W, Kozlitina J, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 2009; 119:70-79.
9. Zhang CC, Kaba M, Ge G, et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 2006; 12:240-245.
10. Zhang CC, Kaba M, Iizuka S, et al. Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood 2008; 111:3415-3423.
11. Ge H, Cha JY, Gopal H, et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 2005; 46:1484-1490.
12. Ge H, Yang G, Yu X, et al. Oligomerization state-dependent hyper-lipidemic effect of angiopoietin-like protein 4. J Lipid Res 2004; 45:2071-2079. (Pubitemid 40990901)
13. Yin W, Romeo S, Chang S, et al. Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem 2009; 284:13213-13222.
14. Jin W, Wang X, Millar JS, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab 2007; 6:129-136.
15. Ono M, Shimizugawara T, Shimamura M, et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem 2003; 278: 41804-41809.
16. Lee EC, Desai U, Gololobov G, et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem 2009;284:13735-13745.
17. 2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J Biol Chem 2009; 284:11942-11952.
18. Sonnenburg WK, Yu D, Lee EC, et al. Glycosylphosphatidylinositol-anchored HDL-binding protein stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. J Lipid Res 2009. [Epub ahead of print]; doi:10.11 94/jlr.M900145-JLR200.
19. Xu Y, Yu Q. Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J Biol Chem 2001; 276: 34990-34998.
20. Xu Y, Liu YJ, Yu Q. Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycans. J Biol Chem 2004; 279:41179-41188.
21. Chomel C, Cazes A, Faye C, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J 2009; 23:940-949.
22. Romeo S, Pennacchio LA, Fu Y, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007; 39:513-516.
23. Talmud PJ, Smart M, Presswood E, et al. ANGPTL4 E40KandT266M. Effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol 2008; 28:2319-2325.
24. Nettleton JA, Volcik KA, Demerath EW, et al. Longitudinal changes in triglycerides according to ANGPTL4[E40K] genotype and longitudinal body weight change in the atherosclerosis risk in communities study. Ann Epidemiol 2008; 18:842-846.
25. Stejskal D, Karṕisek M, Humenanska V, et al. Angiopoietin-like protein 3: development, analytical characterization, and clinical testing of a new ELISA. Gen Physiol Biophys 2007; 26:230-233. (Pubitemid 350186535)
26. Hatsuda S, Shoji T, Shinohara K, et al. Association between plasma angiopoietin-like protein 3 and arterial wall thickness in healthy subjects. J Vasc Res 2007; 44:61-66.
27. Yilmaz Y, Ulukaya E, Atug O, Dolar E. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol 2009. [Epub ahead of print]; doi:10.1097/MEG.0b013e32832b77ae.
28. Shoji T, Hatsuda S, Tsuchikura S, et al. Plasma angiopoietin-like prorein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia. Athero sclerosis 2009. [Epub ahead of print]; doi:10.1016/j.atherosclerosis.2009.05. 023.
29. Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol 2007; 27:366-372.
30. Moon HD, NakajimaK, KamiyamaK, et al. Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects. Clin Chim Acta 2008; 398: 99-104.
31. Miida T, Seino U, Miyazaki O, et al. Probucol markedly reduces HDL phos-pholipids and increased preb1-HDL without delayed conversion into a-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis 2008; 200:329-335.
32. Noto H, Kawamura M, Hashimoto Y, et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis 2003; 171:131-136.
33. Lamarche B, Paradis ME. Endothelial lipase and the metabolic syndrome. Curr Opin Lipidol 2007; 18:298-303.
34. IshidaT, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003; 111:347-355.
35. BadellinoKO, Wolfe ML, Reilly MP, et al. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 2006; 3:e22.
36. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009; 119:1042-1050.
37. Kersten S, Lichtenstein L, Steenbergen E, et al. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol 2009; 29:969-974.
38. Stejskal D, Karṕisek M, Reutova H, et al. Angiopoietin-like protein 4: development, analytical characterization, and clinical testing of a new ELISA. Gen Physiol Biophys 2008; 27:59-63. (Pubitemid 351637903)
39. Staiger H, Haas C, Machann J, et al. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-d and is of metabolic relevance in humans. Diabetes 2009; 58:579-589.
40. Xu A, Lam MC, Chan KW, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA 2005; 102:6086-6091.
41. Mandard S, Zandbergen F, Tan NS, et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 2004; 279:34411-34420.
42. Ebert T, Bachmann A, Lossner U, et al. Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis. Metabolism 2009; 58:547-551.
43. Stepan H, Ebert T, Schrey S, et al. Serum levels of angiopoietin-related growth factor are increased in preeclampsia. Am J Hypertens 2009; 22:314-318.
44. Korstanje R, Eriksson P, Samnegard A, et al. Locating Ath8, a locus for murine atherosclerosis susceptibility and testing several of its candidate genes in mice and humans. Atherosclerosis 2004; 177:433-450.
45. Folsom AR, Peacock JM, Demerath E, Boerwinkle E, et al. Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Metabolism 2008; 57:1591-1596.
46. Adachi H, Fujiwara Y, Kondo T, et al. Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem Biophys Res Commun 2009; 379:806-811.